Mayer Brown advises Novartis on US$7 billion bridge financing and US$5 billion bond offering

London — Global law firm Mayer Brown has advised Novartis AG and Novartis Finance Corporation in connection with a $7 billion short-term (bridge) credit agreement to fund a portion of the purchase price for the acquisition of NASDAQ-listed biopharmaceutical company The Medicines Company for $9.7 billion.

The same core Mayer Brown team also advised Novartis AG and Novartis Capital Corporation in connection with a $5 billion four-tranche SEC-registered bond offering, for which Citigroup Global Markets Inc., HSBC Securities (USA) Inc., Morgan Stanley & Co. LLC and MUFG Securities Americas Inc., Barclays Capital Inc., Deutsche Bank Securities Inc. and Mizuho Securities USA LLC acted as joint book-running managers.

Novartis is a leading global medicines company that uses innovative science and digital technologies to create transformative treatments in areas of great medical need.

The Mayer Brown team included lawyers from the firm’s offices in London, New York and Washington DC and was led by Banking & Finance partner Bernd Bohr (London), supported by Banking & Finance associate Whitney Joseph (London), Tax Transactions & Consulting partner Jared Goldberger and associates Juan Lopez Valek and Brennan Young (all New York) and Financial Services Regulatory & Enforcement partner Jeffrey P. Taft (Washington DC).